| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SBP-0636457 targets Inhibitor of Apoptosis Proteins (IAPs). It binds to the BIR (Baculoviral IAP Repeat) domains of these proteins with a Ki of 0.27 μM. IAPs are a family of proteins that inhibit apoptosis, and their overexpression is a hallmark of many cancers. By antagonizing IAPs, SBP-0636457 promotes apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
At doses up to 20 μM, SBP-0636457 (1-20 μM) shows no cytotoxicity in the breast cancer cell lines BT474, BT549, MCF7, and MDA-MB-231 [1]. With an EC50 of 9 nM, SBP-0636457 (10-1000 nM; 20 h) works well as a TRAIL sensitizer in MDA-MB-231 cells [1].
SBP-0636457 is a potent antagonist of IAPs, binding to their BIR domains with a Ki of 0.27 μM. As a SMAC mimetic, it mimics the action of the endogenous protein SMAC/DIABLO, which promotes apoptosis by inhibiting IAPs. Its in vitro activity is confirmed through binding assays and functional assays measuring the induction of apoptosis in cancer cell lines. |
| ln Vivo |
As a SMAC mimetic, SBP-0636457 is designed to have in vivo activity in treating cancers. While specific in vivo data is not provided, SMAC mimetics are being developed for the treatment of solid tumors and hematologic cancers. They are expected to induce tumor cell death and enhance the efficacy of other cancer therapies.
|
| Enzyme Assay |
The in vitro binding of SBP-0636457 to IAPs is assessed using biochemical assays. The compound is tested for its ability to bind to the BIR domains of IAP proteins, and the Ki value of 0.27 μM is determined from these assays. These assays typically involve competition binding with a labeled ligand.
|
| Cell Assay |
The activity of SBP-0636457 is also evaluated in cell-based assays. As a SMAC mimetic, its ability to induce apoptosis is measured in various cancer cell lines. This is typically done by assessing caspase activation, mitochondrial outer membrane permeabilization, or other markers of apoptosis. Its ability to block pro-survival signaling pathways is also studied.
|
| Animal Protocol |
While specific in vivo protocols are not provided, SBP-0636457 would be evaluated in animal models of cancer. These studies typically involve administering the compound to mice bearing tumor xenografts. Tumor growth inhibition, apoptosis induction, and survival are monitored as endpoints.
|
| ADME/Pharmacokinetics |
SBP-0636457 has a molecular weight of 456.58 and a molecular formula of C25H36N4O4. Its purity is ≥95%. It should be stored at 4°C under nitrogen. It is also known as SBI-0636457. It binds to the BIR-domains of IAP proteins with a Ki of 0.27 μM.
|
| Toxicity/Toxicokinetics |
SBP-0636457 is a SMAC mimetic and IAP antagonist, and its toxicity profile would be expected to be related to its pro-apoptotic mechanism. While it is designed to selectively induce apoptosis in cancer cells, there is potential for on-target toxicity in normal cells. Comprehensive preclinical toxicology studies would be necessary for its development.
|
| References | |
| Additional Infomation |
SBP-0636457 (CAS#: 1422180-49-1) is a SMAC mimetic that antagonizes Inhibitor of Apoptosis Proteins (IAPs) by binding to their BIR domains with a Ki of 0.27 μM. It is being developed for the treatment of solid tumors and hematologic cancers. SMAC mimetics like SBP-0636457 induce apoptotic cancer cell death and block pro-survival signaling.
|
| Molecular Formula |
C25H36N4O4
|
|---|---|
| Molecular Weight |
456.58
|
| Exact Mass |
456.273
|
| CAS # |
1422180-49-1
|
| Related CAS # |
(7R)-SBP-0636457;1422180-61-7
|
| PubChem CID |
76071591
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
757
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1CC[C@H](NC(=O)[C@@H](NC)C)C(=O)N2[C@H](C(N[C@H]3C4=C(C=CC=C4)CCC3)=O)C(C)(C)C[C@]12[H]
|
| InChi Key |
PBGOFGSVVXGJCA-KDJJVYBXSA-N
|
| InChi Code |
InChI=1S/C25H36N4O4/c1-15(26-4)22(30)28-19-12-13-33-20-14-25(2,3)21(29(20)24(19)32)23(31)27-18-11-7-9-16-8-5-6-10-17(16)18/h5-6,8,10,15,18-21,26H,7,9,11-14H2,1-4H3,(H,27,31)(H,28,30)/t15-,18+,19-,20-,21+/m0/s1
|
| Chemical Name |
(4S,7S,9aS)-8,8-dimethyl-4-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-2,3,4,7,9,9a-hexahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~45.71 mg/mL (~100.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.88 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.8 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.88 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.88 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1902 mL | 10.9510 mL | 21.9020 mL | |
| 5 mM | 0.4380 mL | 2.1902 mL | 4.3804 mL | |
| 10 mM | 0.2190 mL | 1.0951 mL | 2.1902 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
